Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.
ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...
US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of ...
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
AMD is the leading cause of central vision loss in the elderly, affecting 200 million people worldwide. AMD's pathogenesis is complex and involves the dysregulation of iron homeostasis, leading to an ...
REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They ...
MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.
ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback